Puma Biotechnology (PBYI) 225.63 $PBYI
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
George Budwell, The Motley Fool - Motley Fool - Thu Apr 16, 10:59AM CDT
After a stellar 2014, Johnson & Johnson 's stock has lagged behind the broader market this year: To gain some insight into this top healthcare stock's weakness so far in 2015, let's dig into the company's first-quarter earnings,...
ACHC: 71.98 (-0.47), JNJ: 100.43 (+0.13), PCYC: 256.98 (-0.77), ISIS: 66.26 (-0.03), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), PFG: 51.73 (+0.73), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
Puma Biotechnology Expands Study Cohort for Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 12:40PM CDT
Puma Biotechnology, Inc. (PBYI) expanded the second cohort in an open-label, multi-center phase II study (basket trial) on its lead candidate neratinib.
CYTK: 7.29 (-0.09), SRDX: 26.57 (+0.02), GWPH: 113.04 (-0.05), PBYI: 225.63 (-4.24)
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Business Wire - Tue Apr 14, 7:45AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation.
PBYI: 225.63 (-4.24)
NYSE stocks posting largest percentage increases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
CBM: 42.07 (-0.65), TCK: 12.87 (-0.03), FC: 19.66 (+0.34), ICD: 8.07 (-0.13), DYN: 33.28 (+0.24), PES: 6.26 (-0.24), SGU: 7.48 (+0.02), ALJ: 16.43 (+0.35), PBYI: 225.63 (-4.24)
Global HER-2 Positive Breast Cancer Market 2015-2019 with Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Sanofi Dominating
M2 - Tue Mar 24, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8rd98/global_her2) has announced the addition of the "Global HER-2 Positive Breast Cancer Market 2015-2019" report to their offering. The analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients. Increased public awareness is a key trend, which is expected to positively impact the growth of the market. Awareness and screening programs can help diagnose potential cases of breast cancer that would otherwise remain undetected till the late stages. According to the report, the increase in the prevalence of breast cancer is a major driver, which is expected to affect the overall market growth in the next five years. With the growing incidence of breast cancer, more and more people are opting for the treatment regimen. Further, the report states that late-stage diagnosis and expensive screening techniques pose a challenge to the market and have a negative impact on the market growth. Expensive screening techniques like mammography screening lead to poor response from patients. Key Vendors - Celgene - F. Hoffmann-La Roche - GlaxoSmithKline - Novartis - Sanofi Other Prominent Vendors - Actavis - Array BioPharma - Biocad - Biocon - Boehringer Ingelheim - Bristol-Myers Squibb - Celltrion - Chugai Pharmaceutical - DARA BioSciences - EddingPharm - Eisai - Galena Biopharma - Halozyme Therapeutics - Hospira - Mylan - Oncothyreon - Pfizer - ProStrakan - Puma Biotechnology - Sun Pharmaceutical Industries - Synta Pharmaceuticals - Teva Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Type of Therapy - Market Segmentation by Molecule Type - Market Segmentation by Route of Administration - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/q8...lobal_her2
SNTA: 2.97 (+0.01), GALE: 1.39 (unch), GSK: 46.57 (-0.67), BMY: 66.60 (-0.21), PBYI: 225.63 (-4.24), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), PCYC: 256.98 (-0.77), OSIR: 16.35 (-0.10), ACOR: 33.34 (-1.33), HSP: 87.80 (+0.04), AGN: 240.22 (+2.88), MDVN: 128.88 (+0.29), ESRX: 86.12 (+0.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), SNY: 51.59 (+0.03), ARNA: 4.47 (+0.01), REGN: 472.63 (+9.41), ABT: 48.35 (+1.23), ENDP: 94.09 (-1.09), AKRX: 53.70 (-1.69), PFE: 34.93 (+0.04), INCY: 107.98 (-1.20), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), MNKD: 4.90 (-0.09), OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), ISIS: 66.26 (-0.03), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), PBYI: 225.63 (-4.24), NVS: 103.45 (-0.62)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), PCYC: 256.98 (-0.77), OSIR: 16.35 (-0.10), ACOR: 33.34 (-1.33), HSP: 87.80 (+0.04), AGN: 240.22 (+2.88), MDVN: 128.88 (+0.29), ESRX: 86.12 (+0.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), SNY: 51.59 (+0.03), ARNA: 4.47 (+0.01), REGN: 472.63 (+9.41), ABT: 48.35 (+1.23), ENDP: 94.09 (-1.09), AKRX: 53.70 (-1.69), PFE: 34.93 (+0.04), INCY: 107.98 (-1.20), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), MNKD: 4.90 (-0.09), OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), ISIS: 66.26 (-0.03), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), PBYI: 225.63 (-4.24), NVS: 103.45 (-0.62)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.35 (+1.23), NWBO: 8.36 (-0.39), ZIOP: 10.88 (+0.03), PCYC: 256.98 (-0.77), CVM: 0.88 (+0.07), PFE: 34.93 (+0.04), CLDX: 28.95 (+1.08), IMGN: 9.96 (+0.01), BMY: 66.60 (-0.21), RIGL: 4.24 (+0.07), INO: 10.39 (-0.09), KITE: 57.56 (-1.43), LH: 126.26 (+0.35), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
Puma Biotechnology Up on Neratinib Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:41PM CDT
Puma Biotechnology (PBYI) announced the initiation of a phase II study on neratinib.
CYTK: 7.29 (-0.09), PFE: 34.93 (+0.04), PBYI: 225.63 (-4.24)
Puma Bio initiates Phase 2 study of neratinib in breast cancer
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:57AM CDT
PBYI: 225.63 (-4.24)
Should Gilead Acquire Puma Biotechnology?
Tim Harrison - at Seeking Alpha - Tue Mar 10, 11:44AM CDT
GILD: 104.18 (-1.02), PBYI: 225.63 (-4.24)
Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Business Wire - Tue Mar 10, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of a Phase II trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer.
PBYI: 225.63 (-4.24)
Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
at The Street - Fri Mar 06, 4:30AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
MDVN: 128.88 (+0.29), NLNK: 53.12 (-0.07), PBYI: 225.63 (-4.24)
The Under-the-Radar Reason Why Puma Biotechnology Inc. Rocketed 17% Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 05, 2:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Puma Biotechnology , a clinical-stage...
PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
Puma Biotechnology beats by $0.16
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:43PM CST
PBYI: 225.63 (-4.24)
Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Mar 02, 3:15PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2014.
PBYI: 225.63 (-4.24)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 35.08 (+0.25), CASM: 1.30 (unch), AMRN: 2.34 (-0.05), XON: 44.53 (+0.36), OSIR: 16.35 (-0.10), CPIX: 6.95 (+0.02), AMED: 26.07 (+0.03), CTIC: 1.93 (+0.09), INSY: 62.10 (+0.76), ECYT: 6.37 (unch), CMRX: 39.73 (+0.65), KYTH: 49.94 (+0.78), TRIB: 17.17 (-0.17), GALE: 1.39 (unch), ARNA: 4.47 (+0.01), XLRN: 33.67 (-0.02), ACRX: 4.50 (-0.07), ENDP: 94.09 (-1.09), DPLO: 34.52 (+0.26), SLXP: 172.96 (+0.15), PPHM: 1.42 (-0.01), MYL: 72.40 (-1.67), CBPO: 99.67 (-0.84), RGEN: 33.37 (+0.51), HALO: 16.03 (+0.15), ALIM: 4.92 (-0.09), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04), DARA: 0.75 (+0.02), SCMP: 21.75 (+0.47), ICPT: 280.45 (-8.26), CDXS: 4.78 (+0.30), PCRX: 83.61 (-0.41), PBYI: 225.63 (-4.24), FOLD: 11.97 (-0.35)
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 18, 3:07PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in an analyst-led fireside chat at 11:30 a.m. EST on Wednesday, February 25, at the 2015 RBC Capital Markets Global Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City.
PBYI: 225.63 (-4.24)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 128.88 (+0.29), BLUE: 136.49 (+1.22), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), TGTX: 16.39 (-0.18), TKMR: 18.38 (-0.14), ANAC: 66.45 (-0.22), PBYI: 225.63 (-4.24), REGN: 472.63 (+9.41)
Johnson & Johnson's Earnings: The Good, The Bad and The Ugly
George Budwell, The Motley Fool - Motley Fool - Thu Apr 16, 10:59AM CDT
After a stellar 2014, Johnson & Johnson 's stock has lagged behind the broader market this year: To gain some insight into this top healthcare stock's weakness so far in 2015, let's dig into the company's first-quarter earnings,...
ACHC: 71.98 (-0.47), JNJ: 100.43 (+0.13), PCYC: 256.98 (-0.77), ISIS: 66.26 (-0.03), SGEN: 36.92 (-0.32), GILD: 104.18 (-1.02), PFG: 51.73 (+0.73), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
Puma Biotechnology Expands Study Cohort for Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 12:40PM CDT
Puma Biotechnology, Inc. (PBYI) expanded the second cohort in an open-label, multi-center phase II study (basket trial) on its lead candidate neratinib.
CYTK: 7.29 (-0.09), SRDX: 26.57 (+0.02), GWPH: 113.04 (-0.05), PBYI: 225.63 (-4.24)
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Business Wire - Tue Apr 14, 7:45AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket trial). The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation.
PBYI: 225.63 (-4.24)
NYSE stocks posting largest percentage increases
AP - Tue Mar 31, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
CBM: 42.07 (-0.65), TCK: 12.87 (-0.03), FC: 19.66 (+0.34), ICD: 8.07 (-0.13), DYN: 33.28 (+0.24), PES: 6.26 (-0.24), SGU: 7.48 (+0.02), ALJ: 16.43 (+0.35), PBYI: 225.63 (-4.24)
Global HER-2 Positive Breast Cancer Market 2015-2019 with Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis & Sanofi Dominating
M2 - Tue Mar 24, 10:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8rd98/global_her2) has announced the addition of the "Global HER-2 Positive Breast Cancer Market 2015-2019" report to their offering. The analysts forecast the Global HER-2 Positive Breast Cancer market to grow at a CAGR of 9.90 percent over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global HER-2 Positive Breast Cancer Market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of targeted therapeutic agents, chemotherapeutic agents, and hormonal therapies that are used in the management of HER-2 positive breast cancer patients. Increased public awareness is a key trend, which is expected to positively impact the growth of the market. Awareness and screening programs can help diagnose potential cases of breast cancer that would otherwise remain undetected till the late stages. According to the report, the increase in the prevalence of breast cancer is a major driver, which is expected to affect the overall market growth in the next five years. With the growing incidence of breast cancer, more and more people are opting for the treatment regimen. Further, the report states that late-stage diagnosis and expensive screening techniques pose a challenge to the market and have a negative impact on the market growth. Expensive screening techniques like mammography screening lead to poor response from patients. Key Vendors - Celgene - F. Hoffmann-La Roche - GlaxoSmithKline - Novartis - Sanofi Other Prominent Vendors - Actavis - Array BioPharma - Biocad - Biocon - Boehringer Ingelheim - Bristol-Myers Squibb - Celltrion - Chugai Pharmaceutical - DARA BioSciences - EddingPharm - Eisai - Galena Biopharma - Halozyme Therapeutics - Hospira - Mylan - Oncothyreon - Pfizer - ProStrakan - Puma Biotechnology - Sun Pharmaceutical Industries - Synta Pharmaceuticals - Teva Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Pipeline Analysis - Market Landscape - Market Segmentation by Type of Therapy - Market Segmentation by Molecule Type - Market Segmentation by Route of Administration - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/q8...lobal_her2
SNTA: 2.97 (+0.01), GALE: 1.39 (unch), GSK: 46.57 (-0.67), BMY: 66.60 (-0.21), PBYI: 225.63 (-4.24), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), PCYC: 256.98 (-0.77), OSIR: 16.35 (-0.10), ACOR: 33.34 (-1.33), HSP: 87.80 (+0.04), AGN: 240.22 (+2.88), MDVN: 128.88 (+0.29), ESRX: 86.12 (+0.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), SNY: 51.59 (+0.03), ARNA: 4.47 (+0.01), REGN: 472.63 (+9.41), ABT: 48.35 (+1.23), ENDP: 94.09 (-1.09), AKRX: 53.70 (-1.69), PFE: 34.93 (+0.04), INCY: 107.98 (-1.20), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), MNKD: 4.90 (-0.09), OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), ISIS: 66.26 (-0.03), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), PBYI: 225.63 (-4.24), NVS: 103.45 (-0.62)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), VRX: 206.93 (-3.92), PCYC: 256.98 (-0.77), OSIR: 16.35 (-0.10), ACOR: 33.34 (-1.33), HSP: 87.80 (+0.04), AGN: 240.22 (+2.88), MDVN: 128.88 (+0.29), ESRX: 86.12 (+0.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91), SNY: 51.59 (+0.03), ARNA: 4.47 (+0.01), REGN: 472.63 (+9.41), ABT: 48.35 (+1.23), ENDP: 94.09 (-1.09), AKRX: 53.70 (-1.69), PFE: 34.93 (+0.04), INCY: 107.98 (-1.20), SLXP: 172.96 (+0.15), AMGN: 169.10 (+0.64), MYL: 72.40 (-1.67), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), ALKS: 62.60 (-0.24), MNKD: 4.90 (-0.09), OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), ISIS: 66.26 (-0.03), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), PBYI: 225.63 (-4.24), NVS: 103.45 (-0.62)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.35 (+1.23), NWBO: 8.36 (-0.39), ZIOP: 10.88 (+0.03), PCYC: 256.98 (-0.77), CVM: 0.88 (+0.07), PFE: 34.93 (+0.04), CLDX: 28.95 (+1.08), IMGN: 9.96 (+0.01), BMY: 66.60 (-0.21), RIGL: 4.24 (+0.07), INO: 10.39 (-0.09), KITE: 57.56 (-1.43), LH: 126.26 (+0.35), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
Puma Biotechnology Up on Neratinib Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:41PM CDT
Puma Biotechnology (PBYI) announced the initiation of a phase II study on neratinib.
CYTK: 7.29 (-0.09), PFE: 34.93 (+0.04), PBYI: 225.63 (-4.24)
Puma Bio initiates Phase 2 study of neratinib in breast cancer
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 11:57AM CDT
PBYI: 225.63 (-4.24)
Should Gilead Acquire Puma Biotechnology?
Tim Harrison - at Seeking Alpha - Tue Mar 10, 11:44AM CDT
GILD: 104.18 (-1.02), PBYI: 225.63 (-4.24)
Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Business Wire - Tue Mar 10, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the initiation of a Phase II trial of Puma's investigational drug PB272 (neratinib) for the extended adjuvant treatment of breast cancer.
PBYI: 225.63 (-4.24)
Biotech Stock Mailbag: Next Biotech Takeout Targets, NewLink Genetics
at The Street - Fri Mar 06, 4:30AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
MDVN: 128.88 (+0.29), NLNK: 53.12 (-0.07), PBYI: 225.63 (-4.24)
The Under-the-Radar Reason Why Puma Biotechnology Inc. Rocketed 17% Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 05, 2:15PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Puma Biotechnology , a clinical-stage...
PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
Puma Biotechnology beats by $0.16
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:43PM CST
PBYI: 225.63 (-4.24)
Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Mar 02, 3:15PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2014.
PBYI: 225.63 (-4.24)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 35.08 (+0.25), CASM: 1.30 (unch), AMRN: 2.34 (-0.05), XON: 44.53 (+0.36), OSIR: 16.35 (-0.10), CPIX: 6.95 (+0.02), AMED: 26.07 (+0.03), CTIC: 1.93 (+0.09), INSY: 62.10 (+0.76), ECYT: 6.37 (unch), CMRX: 39.73 (+0.65), KYTH: 49.94 (+0.78), TRIB: 17.17 (-0.17), GALE: 1.39 (unch), ARNA: 4.47 (+0.01), XLRN: 33.67 (-0.02), ACRX: 4.50 (-0.07), ENDP: 94.09 (-1.09), DPLO: 34.52 (+0.26), SLXP: 172.96 (+0.15), PPHM: 1.42 (-0.01), MYL: 72.40 (-1.67), CBPO: 99.67 (-0.84), RGEN: 33.37 (+0.51), HALO: 16.03 (+0.15), ALIM: 4.92 (-0.09), ACHN: 10.01 (-0.13), GERN: 4.20 (-0.04), DARA: 0.75 (+0.02), SCMP: 21.75 (+0.47), ICPT: 280.45 (-8.26), CDXS: 4.78 (+0.30), PCRX: 83.61 (-0.41), PBYI: 225.63 (-4.24), FOLD: 11.97 (-0.35)
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference
Business Wire - Wed Feb 18, 3:07PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in an analyst-led fireside chat at 11:30 a.m. EST on Wednesday, February 25, at the 2015 RBC Capital Markets Global Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City.
PBYI: 225.63 (-4.24)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 128.88 (+0.29), BLUE: 136.49 (+1.22), BIIB: 423.57 (+1.46), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), TGTX: 16.39 (-0.18), TKMR: 18.38 (-0.14), ANAC: 66.45 (-0.22), PBYI: 225.63 (-4.24), REGN: 472.63 (+9.41)
